501 related articles for article (PubMed ID: 18413796)
41. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
42. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I
Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of Wilms' Tumor Proliferation and Invasion by Blocking TGF-
Shi Q; Wu H; Li Y; Shen L; Tian X; Lin T; Wei G
Biomed Res Int; 2020; 2020():8039840. PubMed ID: 33282954
[TBL] [Abstract][Full Text] [Related]
44. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
[TBL] [Abstract][Full Text] [Related]
45. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Rowland-Goldsmith MA; Maruyama H; Matsuda K; Idezawa T; Ralli M; Ralli S; Korc M
Mol Cancer Ther; 2002 Jan; 1(3):161-7. PubMed ID: 12467210
[TBL] [Abstract][Full Text] [Related]
46. Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.
Shen Z; Seppänen H; Kauttu T; Vainionpää S; Ye Y; Wang S; Mustonen H; Puolakkainen P
J Interferon Cytokine Res; 2013 Aug; 33(8):428-33. PubMed ID: 23651239
[TBL] [Abstract][Full Text] [Related]
47. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
50. Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Kleespies A; Ischenko I; Eichhorn ME; Seeliger H; Amendt C; Mantell O; Jauch KW; Bruns CJ
Clin Cancer Res; 2008 Sep; 14(17):5426-36. PubMed ID: 18765534
[TBL] [Abstract][Full Text] [Related]
51. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Liu Q; Wu H; Li Y; Zhang R; Kleeff J; Zhang X; Cui M; Liu J; Li T; Gao J; Pan B; Wu W; Wang W; Zhou L; Guo J; Dai M; Zhang T; Liao Q; Lu Z; Zhao Y
Cancer Immunol Immunother; 2020 Aug; 69(8):1477-1492. PubMed ID: 32285172
[TBL] [Abstract][Full Text] [Related]
52. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
53. LY2109761, Transforming Growth Factor β Receptor Type I and Type II Dual Inhibitor, is a Novel Approach to Suppress Endothelial Mesenchymal Transformation in Human Corneal Endothelial Cells.
Zhang ZH; Miao YY; Ke BL; Liu K; Xu X
Cell Physiol Biochem; 2018; 50(3):963-972. PubMed ID: 30355908
[TBL] [Abstract][Full Text] [Related]
54. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Feldmann G; Mishra A; Bisht S; Karikari C; Garrido-Laguna I; Rasheed Z; Ottenhof NA; Dadon T; Alvarez H; Fendrich V; Rajeshkumar NV; Matsui W; Brossart P; Hidalgo M; Bannerji R; Maitra A; Nelkin BD
Cancer Biol Ther; 2011 Oct; 12(7):598-609. PubMed ID: 21768779
[TBL] [Abstract][Full Text] [Related]
55. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor.
Zhang L; Zhou F; Drabsch Y; Gao R; Snaar-Jagalska BE; Mickanin C; Huang H; Sheppard KA; Porter JA; Lu CX; ten Dijke P
Nat Cell Biol; 2012 Jun; 14(7):717-26. PubMed ID: 22706160
[TBL] [Abstract][Full Text] [Related]
56. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Sempere LF; Gunn JR; Korc M
Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822
[TBL] [Abstract][Full Text] [Related]
57. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
[TBL] [Abstract][Full Text] [Related]
58. Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
Bartscht T; Rosien B; Rades D; Kaufmann R; Biersack H; Lehnert H; Gieseler F; Ungefroren H
Mol Cancer; 2015 Nov; 14():199. PubMed ID: 26588899
[TBL] [Abstract][Full Text] [Related]
59. Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5.
Zeeh F; Witte D; Gädeken T; Rauch BH; Grage-Griebenow E; Leinung N; Fromm SJ; Stölting S; Mihara K; Kaufmann R; Settmacher U; Lehnert H; Hollenberg MD; Ungefroren H
Oncotarget; 2016 Jul; 7(27):41095-41109. PubMed ID: 27248167
[TBL] [Abstract][Full Text] [Related]
60. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
